Literature DB >> 6285731

Different in vitro effects of dual combinations of anti-herpes simplex virus compounds.

R F Schinazi, A J Nahmias.   

Abstract

Five promising antivirals have been tested individually and in pairs on herpes simplex virus (HSV) types 1 (Strain F) and 2 (Strain G) in Vero cells. These are: 9-(2-hydroxyethoxymethyl)guanine (acyclovir, ACV), 9-beta-D-arabinofuranosyladenine (ara-A), 5-trifluorothymidine (TFT), E-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), and phosphonoformate (PFA). Various types of interactions depending on virus type were observed: synergistic [ara-A/TFT; ara-A/BVDU (G); BVDU/PFA (F)]; additive [ACV/ara-A; ACV/TFT; ACV/BVDU; ACV/PFA (G); BVDU/TFT; PFA/ara-A; PFA/TFT]; and sub-additive [ACV/PFA (F); ara-A/BVDU (F) and BVDU/PFA (G)]. Neither antagonism nor interference was noted for any combinations.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6285731     DOI： 10.1016/0002-9343(82)90061-4

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Herpes simplex virus infections of the central nervous system. Encephalitis and neonatal herpes.

Authors:  R J Whitley
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2.

Authors:  R F Schinazi; J J Fox; K A Watanabe; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

Review 3.  Strategies for antiviral screening targeting early steps of virus infection.

Authors:  Tao Peng
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

4.  Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus.

Authors:  R F Schinazi; J Peters; M K Sokol; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

5.  Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis.

Authors:  R F Schinazi; T C Chou; R T Scott; X J Yao; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

Review 6.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 7.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

8.  Synergistic antiviral activity of acyclovir and interferon on human cytomegalovirus.

Authors:  C A Smith; B Wigdahl; F Rapp
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

Review 9.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.